BlossomHill to present updated Phase 1/2 SOLARA trial data
BlossomHill Therapeutics will present updated Phase 1/2 SOLARA trial data for BH-30643, its macrocyclic OMNI-EGFR inhibitor, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer.
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797SBH-30643 was recently granted Fast Track designation by the FDA for the treatment of C797S-positive resistance in EGFR-mutant NSCLC, a set…